Climb Bio Reports $13.5 Million Net Loss in Q2 2026, Increases Investment in Clinical Pipeline

Climb Bio, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $13.5 million, compared to a net loss of $8.7 million for the same period in 2025. For the six months ending June 30, 2026, the company recorded a net loss of $27.2 million, a slight improvement from the $29.4 million loss reported in the first half of 2025. The increase in losses for the second quarter was attributed to higher operating expenses, which rose to $15.4 million from $10.7 million year-over-year, primarily driven by increased research and development costs associated with the advancement of its product candidates, budoprutug and CLYM116.

In terms of financial position, Climb Bio's total assets increased to $246.3 million as of June 30, 2026, up from $167.7 million at the end of 2025. This growth was largely due to a significant increase in cash and cash equivalents, which rose to $44.1 million from $35.7 million, and short-term marketable securities, which increased to $139 million from $65.4 million. The company’s accumulated deficit also widened to $316.9 million, reflecting ongoing investment in its clinical programs without any product revenue to date.

Strategically, Climb Bio has made notable advancements in its clinical pipeline. The company is actively developing budoprutug, an anti-CD19 monoclonal antibody, for various immune-mediated diseases, including primary membranous nephropathy and immune thrombocytopenia. The company has initiated multiple clinical trials for budoprutug, with ongoing enrollment in a Phase 2 trial for primary membranous nephropathy and a Phase 1b/2a trial for immune thrombocytopenia. Additionally, the company is advancing CLYM116, an anti-APRIL monoclonal antibody, with initial Phase 1 data expected to be reported in the coming months.

Operationally, Climb Bio's employee headcount has increased as the company expands its capabilities to support its clinical development efforts. The company reported a total of 76.2 million weighted-average common shares outstanding as of June 30, 2026, reflecting its recent capital-raising activities, including a private placement that generated approximately $103.4 million in net proceeds. Looking ahead, Climb Bio anticipates continued investment in its research and development programs, with expectations of incurring additional losses as it seeks to bring its product candidates to market. The company has indicated that its current cash and marketable securities are expected to fund operations into the second half of 2028, although it may need to raise additional capital to support its ongoing development efforts.